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Abstract
Introduction: IB kinase ε (IKKε) is a member of the IKK family that plays an important role in the activation of NF-
B. Overexpressed in more than 30% of breast cancers, IKKε has been recently identified as a potential breast
cancer oncogene. The purpose of the present study is to examine the therapeutic potential of IKKε siRNA on
human breast cancer cells.
Methods: Eight siRNAs targeting different regions of the IKKε mRNA were designed, and the silencing effect was
screened by quantitative real-time RT-PCR. The biological effects of synthetic siRNAs on human breast cancer cells
were investigated by examining the cell proliferation, migration, invasion, focus formation, anchorage-independent
growth (via soft agar assay), cell cycle arrest, apoptosis (via annexing binding), NF-B basal level, and NF-B-related
gene expressions upon the IKKε silencing.
Results: Silencing of IKKε in human breast cancer cells resulted in a decrease of focus formation potential and
clonogenicity as well as in vitro cell migration/invasion capabilities. Moreover, knockdown of IKKε suppressed cell
proliferation. Cell cycle assay showed that the anti-proliferation effect of IKKε siRNA was mediated by arresting cells
in the G0/G1 phase, which was caused by downregulation of cyclin D1. Furthermore, we demonstrated that
silencing of IKKε inhibited the NF-B basal activity as well as the Bcl-2 expression. Significant apoptosis was not
observed in breast cancer cells upon the silencing of IKKε. The present study provided the first evidence that
silencing IKKε using synthetic siRNA can inhibit the invasiveness properties and proliferation of breast cancer cells.
Conclusions: Our results suggested that silencing IKKε using synthetic siRNA may offer a novel therapeutic
strategy for breast cancer.
Introduction
IB kinase ε (IKKε, also named IKKi/IKBKE) is a mem-
ber of the IKK family, which contains five distinct but
closely related members: IKKa,I K K b,I K K g, TBK-1 and
IKKε [1,2]. IKK is an important mediator of the activa-
tion of NF-B, which is a heterodimeric transcription
factor playing essential roles in inflammation and cancer
pathogenesis. The NF-B family is composed of Rel A,
Rel B, c-Rel, p50/p105 and p52/p100. Inhibitors of
kappa B (IBs) bind to the homodimers or heterodimers
of NF-B proteins and cause their cytoplasmic retention
in an inactivated form. Upon stimulation, IBs are phos-
phorylated by IKK complexes - which leads to the ubi-
quitination and proteasomal degradation of IBs. NF-B
is then released and translocated into the nucleus to
regulate the expression of target genes involved in
immune and inflammatory responses [3,4]. Discovered
in 2000, IKKε shows a 33% and 31% sequence identity
with IKKa and IKKb, respectively, in the N-terminal
kinase domain, but has distinct function in the activa-
tion of NF-B pathway [2,5]. Overexpression of IKKε is
strongly correlated with the nuclear localization of c-Rel
in breast cancer specimens, indicating that a substantial
fraction of NF-B activation is induced by aberrant
IKKε in breast cancer cells [6]. The relationship between
IKKε and NF-B, however, is not fully understood [4,7].
IKKε is primarily involved in signaling of inflamma-
tory and immune processes [8,9]. Peant and colleagues
reported that overexpression of IKKε in hormone-sensi-
tive LNCaP and 22Rv1 prostate tumor cells induced
secretion of numerous inflammatory cytokines, such as
IL-8 and IL-6. However, the IKKε-dependent IL-8 and
IL-6 overexpressions are not mediated by the activation
* Correspondence: chengkun@umkc.edu
Division of Pharmaceutical Sciences, School of Pharmacy, University of
Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA
Qin and Cheng Breast Cancer Research 2010, 12:R74
http://breast-cancer-research.com/content/12/5/R74
© 2010 Qin et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.of NF-B pathway. Instead, the authors speculated that
high IKKε expression leads to nuclear translocation of
itself to activate these inflammatory cytokine genes [10].
Recently, the role of IKKε in cancer has been studied by
several groups. Sonenshein and colleagues observed for
the first time a higher level of IKKε in breast cancer cell
lines and specimens, whereas little IKKε expression was
detected in normal breast epithelial cells [11]. Further-
more, Boehm and colleagues indentified IKKε as a new
potential oncogene in breast cancer cell lines and
patient-derived tumors using three complementary
genetic approaches. Overexpression of IKKε was
observed in over 30% of breast cancer cell lines and car-
cinomas [4,6,7]. On the other hand, inhibition of IKKε
in breast cancer cells with overexpressed IKKε induced
cell death [6]. All these up-to-date data strongly support
t h er o l eo fI K K ε in tumorigenesis, and subsequently
blocking the IKKε expression would be a rational strat-
egy to treat breast cancer.
Among various strategies to inhibit the oncogene
expression, RNA interference (RNAi) offers considerable
promise for cancer therapy due to its ability to potently
knockdown a specific gene. siRNA of 21 to 23 nucleo-
tides in length silences a target gene by binding to its
complementary mRNA and triggering its degradation
[12,13]. In the present study, we intend to evaluate the
effect of silencing IKKε on colonigenicity, invasive prop-
erties, proliferation, and apoptosis in breast cancer cells
using synthetic siRNA.
Materials and methods
Reagents
Lipofectamine-2000 and TRIzol reagent were purchased
from Invitrogen Corp. (Carlsbad, CA, USA), Cell culture
products were obtained from Atlanta Biologicals, Inc.
(Lawrenceville, GA, USA) and Mediatech, Inc. (Manassas,
VA, USA). BSA was purchased from Sigma-Aldrich
Corporation (St Louis, MO, USA). SYBR Green-1 dye
universal master mix and Multiscript RT were purchased
from Applied Biosystems, Inc. (Foster City, CA, USA).
The 6.5 mm Transwell® with 8.0 μm Pore Polycarbonate
Membrane Insert was purchased from Corning Incorpo-
rated (Lowell, MA, USA). BD Matrigel™ and BD Pharmin-
gen™ Annexin V-FITC Apoptosis Detection Kit I was
o b t a i n e df r o mB DB i o s c i e n c e s( S a nJ o s e ,C A ,U S A ) .T h e
CellTiter-Glo® Luminescent Cell Viability Assay Kit was
purchased from Promega Corp. (Madison, WI, USA).
The NF-B-Met-Luc2 reporter vector was obtained from
Clontech Laboratories, Inc. (Mountain View, CA, USA).
3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was purchased from Research Products
International Corp. (Mt. Prospect, IL, USA). Cisplatin was
obtained from Enzo Life Sciences, Inc. (Plymouth Meeting,
PA, USA). Doxorubicin hydrochloride was purchased from
Thermo Fisher Scientific (Pittsburgh, PA, USA).
Cell lines and culture conditions
All cell lines (human breast cancer cell lines, SK-BR-3
and MCF-7) were purchased from the American Type
Culture Collection, and were maintained in RPMI-1640
medium supplemented with 10% FBS, penicillin (100
unit/ml), and streptomycin (100 μg/ml). Both cell lines
were cultured at 37°C in a humidified atmosphere con-
taining 5% carbon dioxide. The culture medium was
changed every other day and the cells were passaged
when they reached 80 to 90% confluency.
siRNA design and synthesis
siRNAs targeting IKKε [GenBank: NM_014002] were
designed using BLOCK-iT™ RNAi Designer (Invitrogen),
siRNA Target Finder (Ambion, Austin, TX, USA),
siRNA Target Finder (GeneScript, Piscataway, NJ, USA)
and siRNA target Designer (Promega). Eight siRNAs tar-
geting different regions of IKKε mRNA were designed
(Table 1) and were purchased from Ambion and Invi-
trogen. These synthetic siRNAs are of 19 nucleotides
with two thymidine deoxynucleotide (T) 3’ overhangs.
All designed siRNA sequences were blasted against the
human genome database to eliminate cross-silence phe-
nomenon with nontarget genes. Scrambled siRNA
(Ambion) that does not target any gene was used as the
negative control siRNA.
Transfection of siRNA
Cells were transfected with siRNA and Lipofectamine-
2000 according to the manufacturer’s instructions.
Briefly, cells were seeded in a 24-well-plate at a density
of 0.5 × 10
5 cells/well with antibiotics-free medium 12
hours before the transfection. One and a half microliters
of the siRNA (20 μM) were mixed with 1 μlL i p o f e c t a -
mine-2000 in 50 μl serum-free RPMI-1640 medium and
were incubated at room temperature for 25 minutes to
form a complex. After washing cells with PBS, the 50 μl
Table 1 Sense strand sequence of IKKε siRNA [GenBank:
NM_014002]
Number Starting site Sequence
siR-1 482 5’-GGUCUUCAACACUACCAGCtt-3’
siR-2 2538 5’-GGCAUCCUGAAGCAUUAGAtt-3’
siR-3 551 5’-GCUGAACCACCAGAACAUCtt-3’
siR-4 533 5’-GUUUGAGGUCCUGCGGAAGtt-3’
siR-5 820 5’-GCAUCUACAAGCUGACAGAtt-3’
siR-6 1960 5’-GGGAUCAGGUACAUGAGGAtt-3’
siR-7 1968 5’-GUACAUGAGGACAGAAGCAtt-3’
siR-8 1978 5’-ACAGAAGCAUCCAGCAGAUtt-3’
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450 μl RPMI-1640 medium containing 10% FBS at a
final concentration of 50 nM siRNA. Twenty-four hours
after the transfection, the medium was replaced with
fresh 500 μl RPMI-1640 medium containing 10% FBS.
Forty-eight hours after the transfection, cells were col-
lected for RNA and protein isolation.
Real-time RT-PCR
Total RNA was isolated from cells using TRIzol reagent
according to the manufacturer’sp r o t o c o l .T o t a lR N A
(200 ng) was converted to cDNA using random hexamer
primer and MultiScribe Reverse Transcriptase Reagent.
One hundred nanograms of cDNA were amplified by
real-time PCR using SYBR Green-1 dye universal Master
mix on an ABI Prism 5700 Sequence Detection System
(Applied Biosystems). To confirm the PCR specificity,
PCR products were subjected to a melting-curve analysis.
The comparative threshold method was used to calculate
the relative amount of mRNA of treated sample in
comparison with control samples [14,15]. The primers
used for the study included: IKKε,5 ’-ACTCTG-
GAAGTGGCAA GGACAT-3’ (forward) and 5’-TACCT-
GATCCCGGCTCTTCACCA-3’ (reverse); IKKa,5 ’-TCT
GGAACAGCGTGCCATTGATCT-3’ (forward) and 5’-
ATTACTGAGGGCCACTTCCACCTT-3’ (reverse);
IKKb,5 ’-ACTGGAGCAGCAGAAGTACACAGT-3’ (for-
ward) and 5’-ATCAG CATCAGTTGCAGCCACTTC-3’
(reverse); TBK1, 5’-AGGATTGCCTGATCCAGC-
CAAGAT-3’ (forward) and 5’-CCACTGGACGAAG-
GAAGCTTATGC-3’ (reverse); and Bcl-2, 5’-AGGCAT
GTTGACTTCACTTGTGGC-3’ (forward) and 5’-
GCATGCGGCCTCTGTTTGATTTCT-3’ (reverse). We
used 18s ribosomal RNA as an internal control, and the
primers were 5’-GTCTGTGATGCCCTTAGATG-3’ (for-
ward primer), and 5’-AGCTTATGACCCGCACTT AC-
3’ (reverse primer).
Western blotting
The cultured cells were washed twice with ice-cold PBS
and lysed on ice in RIPA lysis buffer containing freshly
added protease and phosphatase inhibitor cocktails.
After 5 minutes of incubation, the cell lysate was col-
lected by centrifugation at 4°C for 10 minutes at 12,000
rpm. The amount of total protein was determined using
a BCA protein assay kit (Pierce, Rockford, IL, USA). An
equal amount of total protein (20 μg) was loaded and
separated by SDS-PAGE. The protein was transferred to
a nitrocellulose membrane, blocked and probed with
appropriate antibodies. The protein was then visualized
using horseradish peroxidase-conjugated secondary anti-
bodies and the FluorChem FC2 imaging system (Alpha
Innotech, San Leandro, CA, USA). Anti-IKKε/IKKi anti-
body (Sigma-Aldrich), anti-b-Actin antibody (Rockland,
Gilbertsville, PA, USA), anti-Bcl2 antibody (Abcam,
Cambridge, MA, USA), anti-cyclin D1 (Abcam) and
horseradish peroxidase-conjugated secondary antibody
(Invitrogen) were used in the western blotting assay.
Focus formation assay
Forty-eight hours after the transfection, 5 × 10
3 MCF-7
cells/well or 7.5 × 10
3 SK-BR-3 cells/well were seeded in
six-well plates. The medium was changed every 2 days.
Cells cultured for 9 days were washed twice with ice-
cold medium, fixed by ice-cold methanol, and stained
with 0.2% crystal violet. Images of the colonies were
obtained using a digital camera.
Soft agar assay
Colony formation ability was examined by anchorage-
independent soft agar assay on MCF-7 cells. Briefly,
1.5 ml FBS supplemented medium containing 0.5% agar-
o s ew e r ea d d e di n3 5 - m mc e l lc u l t u r ed i s h e sa n d
allowed to solidify (base agar). Next, 1 × 10
4 siRNAs
transfected MCF-7 cells were mixed with 1.5 ml FBS-
supplemented medium containing 0.35% agarose and
added to the top of base agar. The cells were then
cultured for 14 days at 37°C under 5% carbon dioxide.
The dishes were stained with 0.005% crystal violet, and
the colonies were examined with microscope and digital
camera.
Wound healing assay
SK-BR-3 cells seeded in 12-well plates (2 × 10
5 cells/well)
were transfected with 50 nM siRNA as described above.
Once the cells reached 90% confluency, a wound area
was carefully created by scraping the cell monolayer with
as t e r i l e1 0μl pipette tip. The cells were then washed
once with Dulbecco’s PBS to remove detached cells. Sub-
sequently, the cells were incubated at 37°C in 5% carbon
dioxide. The width of the wound area was monitored
with an inverted microscope at various time points. The
normalized wound area (wound area48 hours/wound area0
hours) was calculated using the software TScratch [16].
Migration assay and invasion assay
We evaluated the effect of IKKε siRNA on invasiveness
properties of breast cancer cells using transwell migra-
tion and invasion assays. Forty-eight hours after the
transfection, SK-BR-3 cells or MCF-7 cells were trypsi-
nized and resuspended in FBS-free RPMI-1640 medium.
For the migration assay, a total of 1 × 10
5 cells were
plated in the top chamber of the transwell with a non-
coated polycarbonate membrane (6.5 mm diameter
insert, 8.0 μm pore size; Corning Incorporated). For the
invasion assay, 1 × 10
5 cells were plated in the top
chamber of the transwell with a matrigel-coated polycar-
bonate membrane. RPMI-1640 medium with 10% FBS
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After incubation for 48 hours (migration assay) or
60 hours (invasion assay), cells on the lower surface of
the membrane were fixed with 10% formalin and stained
with 0.2% crystal violet. Cells that did not migrate
through the pores were mechanically removed by a cot-
ton swab [17]. The images of migrated cells were
acquired by an inverted microscope with a magnification
of 200×. The number of migrated or invaded cells was
counted from five or six randomly selected fields in a
blind way.
Cell proliferation assay
The effect of siRNA on cell proliferation was measured
using the CellTiter-Glo® Luminescent Cell Viability Assay
Kit (Promega) according to the manufacturer’sp r o t o c o l .
Briefly, SK-BR-3 cells (5,000 cells/well) or MCF-7 cells
(2,500 cells/well) seeded in 96-well plates were trans-
fected with 50 nM siRNA as described above. Seventy-
two hours and 120 hours after the transfection, 100 μl
CellTiter-Glo® reagent was added to each well that con-
tained 100 μl cell culture medium. Cells were then lysed
by shaking in an orbital shaker for 2 minutes, followed by
incubation at room temperature for 10 minutes to stabi-
lize the luminescent signal. The luminescent intensity
was measured using a Beckman DTX 880 multimode
Detector (Beckman coulter, Inc., Brea, CA, USA).
NF-B transcriptional activity assay
The transcriptional activity of NF-B was examined
using a Ready-To-Glow™ secreted luciferase reporter
system, NF-B-Met-Luc2, which contains the NF-B
promoter element upstream of the luciferase gene. The
expression of luciferase was used to monitor the activity
of NF-B. Fifty thousand SK-BR-3 cells or MCF-7 cells
were seeded in 24-well plates and transfected with
siRNAs. Twenty-four hours after siRNA transfection, the
cells were co-transfected with NF-B-Met-Luc2 reporter
vector and b-galactosidase reporter vector (used as an
internal control). The culture medium was collected
24 hours post-transfection to measure the luciferase
activity. The cells were lysed with reporter lysis buffer
and the b-galactosidase activities of whole cell lysate
were measured. The relative luciferase activity was calcu-
lated by normalizing results with the b-galactosidase
expression.
Cell cycle assay and apoptosis assay
Forty-eight hours after the siRNA transfection, the cells
were collected and fixed with ice-cold 70% ethanol.
Before staining, the cells were washed with Dulbecco’s
PBS and incubated with propidium iodide/RNase stain-
ing buffer for 30 minutes at room temperature. Cell
cycle analysis was carried out with a FACSCalibur Flow
cytometer (BD Biosciences). To analyze apoptosis, cells
were collected 72 hours post-transfection, and then
stained with Annexin V-FITC and propidium iodide
using the Annexin V-FITC Apoptosis Detection Kit I.
The percentage of apoptotic cells was quantified by a
FACSCalibur Flow cytometer. Paclitaxel (100 nM,
2 4 - h o u ri n c u b a t i o n )w a su s e di nt h ea p o p t o s i sa s s a ya s
an apoptosis inducer to validate the measurements.
Combinational treatment of cells with siRNA and
chemotherapy agents
Cells (10,000 cells/well) were seeded in a 96-well plate
and transfected with siRNA as described above. Twenty-
four hours after the transfection, the cells were incubated
with medium supplemented with serial concentrations of
cisplatin and doxorubicin for another 24 hours. Untrans-
fected cells treated with different concentration of cispla-
tin or doxorubicin are defined as medium control group.
Cell viability was then determined by MTT assay. MTT
in PBS was added into cells at a final concentration of
0.5 mg/ml. After 1 hour of incubation at 37°C, the med-
i u mw a sa s p i r a t e da n d1 0 0μl dimethylsulfoxide was
added to dissolve the cells and the absorbance was mea-
sured at 570 nm.
Statistical analysis
Data were expressed as the mean ± standard deviation.
Difference between any two groups was determined by
analysis of variance. P < 0.05 was considered statistically
significant.
Results
Silencing of IKKε gene by predesigned siRNAs
To silence IKKε e x p r e s s i o n ,w ed e s i g n e du pt oe i g h t
siRNAs (Table 1) targeting different mRNA regions of
IKKε. Silencing effects of these predesigned IKKε siR-
NAs were examined in SK-BR-3 cells at a concentration
of 50 nM after complexation with Lipofectamine-2000.
A scrambled siRNA that does not target any gene was
used as the negative control. All eight siRNAs showed a
significant silencing effect (P < 0.05) and knocked down
55.2 to 77.9% of IKKε mRNA in comparison with
scrambled siRNA (Figure 1a). Among them, siR-1 and
siR-8 showed the greatest suppression of IKKε and
therefore these two siRNAs were selected for subse-
quent biological studies. Considering the fact that
siRNA transfection efficiency may vary in different cell
lines, we also examined the silencing effects of siR-1
and siR-8 in MCF-7 cells. Approximately 61.3% and
59.0% of IKKε mRNA were silenced in MCF-7 cells
after treatment with siR-1 and siR-8 (Figure 1b), respec-
tively. The silencing effect of IKKε expression at the
protein level was also confirmed with western blot. As
shown in Figure 1c, both siR-1 and siR-8 significantly
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and MCF-7 cells, which is consistent with the silencing
effect at the mRNA level.
To study whether IKKε silencing upregulates other
IKK kinases, we assayed the mRNA expression of IKKa,
IKKb and TBK1 after silencing IKKε in MCF-7 cells and
SK-BR-3 cells (Figure 2e, f). In both cell lines, IKKε sup-
pression did not significantly influence the expressions
of IKKa, IKKb and TBK1 (P > 0.05).
Silencing of IKKε inhibits focus formation of breast
cancer cells
First, we used a focus formation assay to test whether
silencing IKKε in breast cancer cells affects the clono-
genic potential, which correlates with tumor formation
in vivo [18]. Forty-eight hours after the transfection, a
single-cell suspension was seeded into six-well plates
and incubated for 9 days to allow focus formation. The
cells’ foci were fixed, stained with crystal violet, and
counted. As Figure 2a shows, SK-BR-3 cells treated
with IKKε siRNA exhibited smaller focus diameter as
well as focus numbers compared with cells treated
with the scrambled siRNA. Similar results were also
observed in MCF-7 cells (Figure 2b). These data indi-
cated that inhibition of IKKε significantly decreases the
cells’ focus formation potential, which correlates with
the formation of tumors in nude mice [19].
Silencing IKKε inhibits anchorage-independent growth of
breast cancer cells
Anchorage-independent growth capability is one of the
important characteristics of oncogenically transformed
Figure 1 Silencing effect of predesigned IKKε siRNAs in SK-BR-3 and MCF-7 cells. (a) SK-BR-3 cells were transfected with eight predesigned
IKKε siRNAs (siR-1 to siR-8) and negative control siRNA (NC) at a concentration of 50 nM. Cells were harvested 48 hours after the transfection,
and the silencing effect at the IKKε mRNA level was determined using real-time RT-PCR. (b) MCF-7 cells were transfected with selected siR-1, siR-
8, and NC. The Silencing effect at the IKKε mRNA level was measured using real-time RT-PCR. The silencing effect of IKKε siRNA at the protein
level was determined using western blot in (c) SK-BR-3 cells and (d) MCF-7 cells. The effect of IKKε suppression on IKKa, IKKb and TBK1was
examined in (e) SK-BR-3 cells and (f) MCF-7 cells.
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influence the anchorage-independent growth potential,
we performed a soft agar assay in MCF-7 cells. Twenty-
four hours after the transfection, a single-cell suspension
was seeded into 0.35% agarose supplemented with
RPMI-1640 medium and 10% FBS. The cells were cul-
tured for another 14 days under normal cell culture
conditions to allow colony formation. As shown in
Figure 2e, silencing IKKε in MCF-7 cells dramatically
inhibited the transformed phenotype. Individual colony
size was much smaller in IKKε siRNA transfected cells
compared with negative control siRNA-treated cells.
This result indicated that silencing of IKKε in breast
cancer cells suppress anchorage-independent growth
capability.
Silencing of IKKε inhibits cell motility and invasion
Decreased clonogenic potential is usually associated with
the loss of invasion capabilities in tumor cells [18]. The
cell motility of breast cancer cells was therefore tested
using a classic wound heali n ga s s a yi nw h i c ht h ec e l l
monolayer was scratched and cells migrating to the
wound area were monitored at different time points.
Compared with cells transfected with scrambled siRNA,
the cells treated with siR-1 and siR-8 showed a wider
wound area 48 hours after wound generation, and took
a longer time to fill the wound area, indicating a defect
in migration (Figure 3).
Since both cell migration and invasion are critical
properties for the spreading of cancer cells and metas-
tases, we further investigated the cell invasiveness using
in vitro migration and invasion assays. Migration assay
using uncoated Boyden chamber is a common method
to examine the in vitro migration ability of tumor cells.
Cells that migrated to the bottom of the transwell were
fixed, stained and counted. Compared with the control
group, IKKε siRNA transfected cells showed a significant
decrease in the number of migrated cells in MCF-7 cells
Figure 2 Silencing of IKKε inhibits focus formation and colony formation. Forty-eight hours after the siRNA transfection, (a) SK-BR-3 cells
and (b) MCF-7 cells were seeded in six-well plates, and the medium was changed every 2 days. Cells cultured for 9 days were washed twice
with ice-cold medium, fixed with ice-cold methanol, and stained with 0.2% crystal violet. Images of the colonies were obtained with a digital
camera. (c), (d) The focus number was counted and the result represented as mean ± standard deviation (n = 3). (e) A soft agar assay was
conducted to examine the colony formation ability of MCF-7 cells. Twenty-four hours after the siRNA transfection, MCF-7 cells were seeded in
0.35% agarose in RPMI-1640-supplemented 10% FBS at a density of 1 × 10
4 per 35-mm culture dish and allowed to grow for 14 days. Results are
representative picture of colonies of two independent experiments done in triplicate. *P < 0.05. NC, negative control siRNA.
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coated transwell chambers were used to access the inva-
sive capacities of breast cancer cells. Consistent with the
finding in migration assay, cells treated with IKKε
siRNA demonstrated significant reduction in cell inva-
sion ability by 50 to 70% in SK-BR-3 cells and 30 to
73% in MCF-7 cells in comparison with scrambled
siRNA-treated cells (Figure 4a, b). Taken together, these
results indicate that silencing of IKKε decreases the
invasive properties of breast cancer cells.
Silencing of IKKε inhibits the proliferation of breast
cancer cells
Since oncogene is known to facilitate tumor cell growth,
we next examined the proliferation of breast cancer cells
after silencing of IKKε with siRNA. Cell growth was
determined at 72 hours and 120 hours post-transfection.
Compared with cells transfected with the scrambled
siRNA, cells treated with IKKε siRNAs demonstrated
slower growth rate and lower viability (Figure 5). This
observation is in accordance with the finding that a len-
tiviral shRNA targeting IKKε suppressed the prolifera-
tion and viability of MCF-7 cells [6]. These results
suggested the pivotal role of IKKε in the proliferation
and survival of breast cancer cells, and suppression of
IKKε could lead to inhibition of cell proliferation. More-
over, the inhibition effect on cell proliferation is more
significant at 120 hours rather than 72 hours post-
transfection.
Silencing of IKKε induces cell arrest in G0/G1 phase
To identify the mechanism for this anti-proliferation
effect, we investigated the cell cycle distribution of breast
cancer cells after the silencing of IKKε.A sF i g u r e6
Figure 3 Study of cell motility by wound healing assay. A wound healing assay was used to evaluate the migration of SK-BR-3 cells after
silencing IKKε. Fifty-six hours after the transfection of siRNA, cells were wounded and monitored with a microscope every 12 hours. The
migration was determined by the rate of cells filling the scratched area. The normalized wound area was calculated by the software TScratch
[16]. Similar results were obtained in three independent experiments. NC, negative control siRNA.
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nificant G0/G1 block in comparison with cells treated
with scrambled siRNA. This was accompanied by a
reduction of the proportion of M-phase cells, while there
was little difference in the G2/M distribution. The G0/G1
distribution of SK-BR-3 cells transfected with IKKε siR-1
and siR-8 was 59.2% and 64.4%, respectively, in compari-
son with 50.4% in cells treated with scrambled siRNA
(Figure 6a). In the same experiment, a similar result was
observed in MCF-7 cells (Figure 6b). The percentages of
cells in the G0/G1 phase were 61.1% and 61.8% for cells
treated with siR-1 and siR-8, respectively. In comparison,
only 54.3% of MCF-7 cells treated with scrambled siRNA
were in the G0/G1 phase. The data revealed that IKKε
siRNA inhibits cell proliferation via blocking cell cycle
progression at the G0/G1 phase.
Figure 4 Silencing of IKKε expression inhibits migration and invasion abilities of SK-BR-3 cells and MCF-7 cells.C e l lm i g r a t i o nw a s
determined using Boyden transwell chambers. Forty-eight hours after the transfection with siRNA, (a) SK-BR-3 cells and (b) MCF-7 cells were
suspended in serum-free medium and seeded on 24-well transwell plates. RPMI-1640 with 10% FBS was incubated in the lower chamber as the
chemoattractant. Cells migrated though pores to the bottom surface of the transwell were fixed with 10% buffered formalin, stained with 0.2%
crystal violet and counted. Six random microscopic fields were counted for each group. Cell invasion was assayed in transwell coated with
Matrigel. Cells crossed the Matrigel-coated filter were fixed, stained and counted. Representative pictures of the bottom surface are shown. Six
random microscopic fields were counted for each group. The results presented are an average of six random microscopic fields from three
independent experiments. Significant reduction of migration and invasion was observed after silencing IKKε expression in SK-BR-3 cells and
MCF-7 cells. *P < 0.05. NC, negative control siRNA.
Figure 5 Effect of IKKε siRNA on cell proliferation. (a) SK-BR-3 cells and (b) MCF-7 cells were transfected with siR-1, siR-8, and negative
control siRNA (NC). Cell growth was assayed at 72 hours and 120 hours post-transfection using the CellTiter-Glo® Luminescent Cell Viability
Assay Kit. Result represented as mean ± standard deviation (n = 3). RLU, Relative Luminescence Unites.
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Flow cytometry was next used to assay the apoptosis of
breast cancer cells after inhibition of IKKε using siRNA.
No significant difference of Annexin-V-positive apopto-
tic cells was observed in the IKKε siRNA-treated group
in comparison with cells transfected with scrambled
siRNA. As Figure 7 indicated, IKKε-specific siRNA, siR-
1 and siR-8, induced apoptosis in 4.0% and 6.4% of SK-
BR-3 cells, respectively, while the scrambled siRNA
induced apoptosis in 5.9% of cells (P =0 . 8 2 1 ) .I nM C F -
7 cells, siR-1, siR-8, and scrambled siRNA induced
apoptosis in 10.2%, 14.7% and 11.2% of cells respectively
(P = 0.266). No significant difference was observed in
this study, suggesting that knockdown of IKKε alone
may not induce apoptosis of breast cancer cells.
Silencing of IKKε decreases the basal activity of NF-B
To determine whether the knockdown of IKKε gene
affects the constitutive NF-B activity in breast cancer
cells, the NF-B-dependent luciferase reporter assay was
performed. Cells were transfected with siRNA for 24
hours, followed by co-transfection with the NF-B-
MetLuc2 reporter vector and the b-galactosidase repor-
ter vector, which was used as an internal control to
normalize the transfection efficiency. As shown in
Figure 8, the NF-B transcriptional activity was reduced
Figure 6 Silencing of IKKε leads to G0/G1 phase arrest. Cell cycle distribution of (a) SKBR-3 cells and (b) MCF-7 cells treated with 50 nM siR-
1, siR8, and scrambled siRNA were accessed by flow cytometry 48 hours post-transfection. Results are representative of three independent
experiments, represented as mean ± standard deviation (n = 3). NC, negative control siRNA.
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cells treated with scrambled siRNA. In MCF-7 cells, the
NF-B basal level in IKKε siRNA-treated cells decreased
to around 42 to 46% of the control group. Similar result
was also observed in SK-BR-3 cells, where the NF-B
basal level decreased to approximately 47 to 58% of the
control group upon IKKε silencing. This result suggests
that IKKε may play an important role in controlling the
NF-B dependent activity in breast cancer cells. This is
in agreement with the finding that IKKε activates the
NF-B pathway in breast cancer, although the mechan-
ism is not fully elucidated [6,11].
Silencing of IKKε regulates NF-B-related downstream
genes
It is reported that breast cancer cells overexpressing IKKε
showed increased expression of Bcl-2 compared with
cells without IKKε overexpression [6]. The Bcl-2 expres-
sion levels in SK-BR-3 cells and MCF-7 cells were there-
fore examined after the inhibition of IKKε. As indicated
in Figure 9a, b, the Bcl-2 mRNA level decreased in both
SK-BR-3 cells and MCF-7 cells after the treatment with
siR-1 and siR-8. This is in accordance with a previous
finding that suppression of the IKKε gene resulted in
downregulation of Bcl-2 expression [6]. We also exam-
ined the protein level of Bcl-2 using western blot (Figure
9c, d). Consistent with the mRNA results, both SK-BR-3
cells and MCF-7 cells showed reduction of Bcl-2 protein
expression after the IKKε siRNA treatment. Image J soft-
ware was used to normalize the Bcl-2 expression with
b-actin. In SK-BR-3 cells, the normalized Bcl-2
expressions of siR-1 and siR-8 siRNA treated cells were
40% and 66%, respectively, in comparison with the con-
trol group. In MCF-7 cells, the normalized Bcl-2 expres-
sions of siR-1 and siR-8 siRNA-treated cells were 88%
and 48%, respectively, in comparison with the control
group.
Since cyclin D1 w a sr e p o r t e da st h ek e yr e g u l a t o r y
protein for progression through the G1 phase of breast
cancer cells [20], we next examined whether the expres-
sion of cyclin D1 was responsible for the G0/G1 cell
cycle arrest in IKKε siRNA-treated cells. As Figure 9c, d
indicates, silencing of IKKε significantly decreased the
expression of cyclin D1 in breast cancer cells. In SK-BR-
3 cells, the normalized Bcl-2 expressions of siR-1 and
siR-8 siRNA-treated cells were 64% and 34%, respec-
tively, in comparison with the control group. In MCF-7
cells, the normalized Bcl-2 expressions of siR-1 and
siR-8 siRNA-treated cells were 71% and 45%, respec-
tively, in comparison with the control group. Overex-
pression of cyclin D1 has been shown to shorten the G1
phase, and subsequently increase the cell proliferation
[21]. This result therefore suggests that cyclin D1 is an
important mediator in the oncogenic role of IKKε in
breast cancer.
Inhibition of NF-B has been reported to sensitize
breast cancer cells to doxorubicin [22]. Overexpression
of IKKε is associated with cell resistance to cisplatin in
ovarian cancer. Silencing of IKKε sensitized ovarian can-
cer cells to cisplatin-induced apoptosis and cell death
[23]. Moreover, IKKε is an important mediator that pro-
tects cells from DNA-damage-induced cell death [24].
Figure 7 Effect of IKKε siRNA on apoptosis of breast cancers. (a) SK-BR-3 cells or (b) M C F - 7c e l l sw e r et r a n s f e c t e dw i t hs i R - 1 ,s i R - 8 ,a n d
scrambled siRNA at 50 nM. Seventy-two hours after transfection, cells were stained with Annexin-V-FITC and propidium iodide followed by flow
cytometry. The percentage of early apoptotic (right bottom), late apoptosis (right top), and necrotic cells are shown. Three independent
experiments were conducted. NC, negative control siRNA.
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Page 10 of 15Figure 8 Silencing of IKKε expression reduces basal NF-B transcriptional activity in SK-BR-3 cells and MCF-7 cells. Twenty-four hours
after the siRNA transfection, (a) SK-BR-3 cells and (b) MCF-7 cells were co-transfected with the NF-B Met Luc2 reporter vector, which contains
the NF-B promoter element upstream of the luciferase gene, and the b-galactosidase reporter vector as an internal control. The expression of
luciferase was used to monitor the transcriptional activity of NF-B. The relative luciferase activity was normalized with the b-galactosidase
expression. Result representative of three independent experiments. * P < 0.05. NC, negative control siRNA; RLU, Relative Luminescence Unites.
Figure 9 Silencing of IKKε leads to reduction of Bcl-2 and cyclin D1 in breast cancer cells. The Bcl-2 mRNA level was determined in (a) SK-
BR-3 cells and (b) MCF-7 cells using real-time RT-PCR. The relative levels of Bcl-2 mRNA in the scrambled siRNA group were normalized as 100%.
Results represented as mean ± standard deviation (n = 3). IKKε, Bcl-2 and cyclin D1 expressions at the protein level were assayed using western
blot in IKKε siRNA-transfected (c) SK-BR-3 cells and (d) MCF-7 cells. NC, negative control siRNA.
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IKKε silencing can sensitize the response of breast can-
cer cells to chemotherapy reagents. Herein we investi-
gated the response of breast cancer cells to cisplatin and
doxorubicin after silencing IKKε.M C F - 7c e l l sa n dS K -
BR-3 cells were transfected with 50 nM IKKε siRNA or
scrambled siRNA, followed by incubation with different
concentrations of cisplatin or doxorubicin. After
24 hours of incubation, cell viability was measured by
the MTT assay. As Figure 10 showed, IKKε suppression
did not sensitize breast cancer cells to cisplatin (10 to
100 μM) (Figure 10a, b) and doxorubicin (0.1 to 10 μM)
(Figure 10c, d).
Discussion
The NF-B pathway plays an important role in immune
response, inflammation, and cancer development [25].
As a recently indentified kinase in the NF-Bp a t h w a y ,
IKKε is upregulated in a great proportion of breast can-
cer cells as well as tumor specimens [6]. Our findings
support the hypothesis that IKKε plays an important
role in the tumorigenesis of breast cancer.
IKKε plays an important role in cell transformation,
and activation of the NF-B pathway is involved in the
IKKε-mediated transformation [6]. The tumor suppres-
sor CYLD is directly phosphorylated by IKKε at serine-
418 to decrease its deubiquitinase activity, which is
essential to the IKKε-induced transformation [7]. More-
over, breast cancer cells Hs578T stably expressing IKKε
K38A (kinase-inactive IKKε) showed dramatically low
colony formation ability in soft agar compared with cells
transfected with the control vector (pCDNA3-FLAG-
IKKε) [11]. Consistent with these observations, we
found that silencing of IKKε with siRNA led to signifi-
cant reduction in focus formation in both MCF-7 cells
and SK-BR-3 cells (Figure 2).
Several lines of evidence implicate that NF-Ba n d
NF-B-related IKKs are involved in cell invasion and
tumor metastasis [26,27]. For example, prevention of
IKKa activation resulted in inhibition of prostate cancer
Figure 10 Knockdown of IKKε does not sensitize SK-BR-3 cells and MCF-7 cells to cisplatin and doxorubicin. Twenty-four hours after the
siRNA transfection, (a), (c) SK-BR-3 cells and (b), (d) MCF-7 cells were treated with indicated amounts of (a), (b) cisplatin or (c), (d) doxorubicin
for 24 hours, and the cell viability was measured by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results represented
as mean ± standard deviation (n = 3). NC, negative control siRNA.
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conducted numerous experiments including the would-
healing assay, migration assay, and invasion assay to
assess the effect of IKKε siRNA on invasiveness proper-
ties of breast cancer cells. As shown in Figures 3 and 4,
the invasiveness properties were significantly inhibited
in cells treated with the IKKε siRNA in comparison
with cells treated with the scrambled siRNA. These data
are consistent with a previous report that breast cancer
cells (NF639) transfected with IKKε K38A (kinase-inac-
tive) vectors induced a less invasive phenotype com-
pared with cells transfected with vectors expressing the
active IKKε [11].
Recent studies have shown that IKKε knockdown with
lentiviral shRNA inhibited the proliferation and survival
of transformed breast cancer cells, but not the nontrans-
formed human mammary epithelial cells (MCF-10A) [6].
A similar inhibition effect on cell proliferation was also
observed in IKKε knockdown Hela cells and ovarian
cancer cells [4,23]. In agreement with these findings, we
observed a significant anti-proliferation effect of IKKε
siRNA in breast cancer cells (Figure 5). To further eluci-
date the mechanism of this anti-proliferation effect, cell
cycle analysis was conducted. A significant cell cycle
arrest in the G0/G1 phase was observed (Figure 6). All
t h e s ed a t as t r o n g l ys u g g e s tt h er o l eo fI K K ε in breast
cancer proliferation.
We next examined the effect of IKKε on cell apopto-
sis. There is some controversy regarding the role of
IKKε in cell apoptosis. It has been reported that IKKε
inhibition induces apoptosis in Hela cells [29]. Another
report using lentiviral shRNA targeting IKKε, however,
did not show any apoptosis in ovarian cancer cells
(A2780). Instead, overexpression of IKKε was found
associated with cisplatin resistance. Significant apoptosis
was detected in IKKε knockdown A2780 cells after
20 hours of exposure to cisplatin in comparison with
cells treated with cisplatin alone [23]. In the current
study, we did not observe significant apoptosis in IKKε
knockdown SK-BR-3 and MCF-7 cells after silencing
IKKε using siRNA.
Although the relationship between IKKε and NF-Bi s
not fully understood, it was postulated that a significant
fraction of NF-B activation was induced by aberrant
IKKε expression in tumor cells [4,6,7]. Using the NF-B
transcriptional activity assay, we showed a significant
reduction in basal NF-B activity after IKKε suppression
(Figure 8). This result is in agreement with a previous
finding that IKKε knockdown in Hela cells reduced con-
stitutive activity of the NF-B dependent promoter
3X-B [4]. The correlation of IKKε with NF-Bm a y
explain the role of IKKε in malignant transformation
and invasiveness of tumor cells.
Moreover, we examined the expression of Bcl-2 and
cyclin D1, which are two important proteins regulated
by the NF-B pathway. Bcl-2 is an important apoptosis
regulator involved in processing multiple death signals
that are associated with mitochondria [30]. The Bcl-2
expression level correlates with chemotherapy resistance
[31-33]. Downregulation of Bcl-2 results in induction of
apoptosis and increased sensitivity to chemotherapy
drugs [34,35]. Knockdown of Bcl-2 in MCF-7 cells using
siRNA, however, only increased apoptosis by 9% (at
72 hours) and 11% (at 96 hours) in comparison with the
control group [36]. In addition, Akar and colleagues
demonstrated that cell death (MCF-7 cells) triggered by
Bcl-2 siRNA was caused by the induction of autophagic
cell death rather than apoptosis. The authors did not
observe any apoptosis effect in breast cancer cells upon
Bcl-2 silencing [37]. These controversial reports sug-
gested that downregulation of the anti-apoptosis protein
Bcl-2 alone does not necessarily result in apoptosis,
especially considering the fact that induction of apopto-
sis is determined by a balance of multiple pro-apoptosis
proteins and anti-apoptosis proteins [38]. Similar to
these findings, we only observed negligible apoptosis in
breast cancer cells (Figure 7), although the Bcl-2 level
was downregulated by the IKKε siRNA (Figure 9a to
9c). These results might be explained by a compensation
of other existed anti-apoptosis factors. In addition, the
treatment of IKKε siRNA did not sensitize breast cancer
cells to cisplatin and doxorubicin (Figure 10), indicating
that silencing IKKε alone may not be sufficient to
induce cell apoptosis.
On the other hand, significant inhibition of cyclin D1
was observed in cells treatment with IKKε siRNA (Figure
9d). Cyclin D1, regulated by the NF-B pathway, is overex-
pressed in more than 50% of breast cancers, and is identi-
fied as one of the most commonly upregulated proteins in
breast cancer [39,40]. There is mounting evidence that
cyclin D1 plays a critical role in breast cancer cell cycle
control. The induction of cyclin D1 in breast cancer
cells shortens the G1 phase and increases the number of
cells that progress through the G1 phase, resulting in an
increased proliferation [21]. It was reported that overex-
pression of an inactive mutant of IKKε (K38A) in Hs578T
cells resulted in reduction of cyclin D1 [11]. A recent study
showed that IKKε phosphorylates estrogen receptor a at
serine-167 and subsequently transcriptionally upregulates
cyclin D1 [41]. Our results showed that cyclin D1 expres-
sions were downregulated upon IKKε knockdown in both
estrogen receptor-positive (MCF-7) and estrogen receptor-
negative (SK-BR-3) breast cancer cells (Figure 9c, d), and
the reduced cyclin D1 expressions in both breast cancer
cell lines were correlated with a cell cycle arrest in G0/G1
(Figure 6a, b).
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In summary, studies from our laboratory have shown that
silencing of IKKε with siRNA resulted in significant inhibi-
tion of focus formation potential, anchorage-independent
growth capability, migration, invasiveness, and prolifera-
tion in breast cancer cells. The NF-B transcriptional
activity and its downstream gene, cyclin D1,w e r ei n h i b i t e d
by IKKε siRNAs. The anti-proliferation effect of IKKε
siRNA is mediated by arresting cells in the G0/G1 phase.
The present study provided the first evidence that silen-
cing IKKε using synthetic siRNA inhibited the invasiveness
and proliferation of breast cancer cells. Taken together,
our findings not only indicate that IKKε can be a novel
therapeutic target for breast cancer treatment, but also
suggest a therapeutic potential of targeting IKKε with
siRNA.
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